Table 19.8 Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Surviva	-1 /Dansant)								
Year of Diagnosis:	ai (Percent)								
1960-1963 ^a		_	_	31	31	31	_		_
1900-1903 1970-1973 ^a	_ _	_	<u>-</u>	41	39	43	_	_	_
1975-1973 1975-1977 ^b	46.5	45.6	47.5	46.8	46.3	47.3	48.6	42.6	55.3 ^g
1975-1977 ^a 1978-1980 ^b	40.5	46.1	47.5	46.8 47.9	46.3	47.3	48.6 51.3	42.6	55.3
1978-1980° 1981-1983 ^b	47.9 50.5	50.2	49.8 50.9				49.4		49.8
				50.7	50.4	51.0		49.0	
1984-1986 ^b	51.5	49.9	53.3	51.9	50.4	53.6	46.8	44.5	49.9
1987-1989 ^b	50.9	47.6	54.9	51.3	48.1	55.2	45.9	41.7	51.0
1990-1992 ^b	50.7	46.7	55.7	51.5	47.6	56.4	42.2	38.2	47.7
1993-1995 ^b	52.5	48.7	57.4	53.2	49.7	57.6	42.1	35.7	54.0
1996-1998 ^b	58.8	57.0	61.0	59.4	57.6	61.4	54.7	53.2	56.9
1999-2001 ^b	63.9	61.4	66.9	64.9	62.8	67.5	55.7	48.9	63.8
2002-2004 ^b	69.7	68.5	71.2	71.0	70.1	72.1	63.5	60.9	66.5
2005-2011 ^b	71.9 ^f	70.8 ^f	73.3 ^f	73.0 ^f	72.1 ^f	74.0 ^f	64.0 ^f	59.2 ^f	69.0 ^f
5-Year Period Survival	(Percent) ^{cd}								
2011	70.6	69.1	72.3	71.1	69.8	72.7	63.7	60.3	67.6
Stage Distribution (%) All Stages	2005-2011 ^{ce}								
Number of cases	93,276	50,477	42,799	77,757	42,131	35,626	7,576	4,093	3,483
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	28	27	29	27	26	29	28	25	31
Regional	15	15	15	15	15	15	15	14	15
Distant	50	51	47	50	52	48	51	55	47
Unstaged	8	7	8	7	7	8	7	6	7
3			Ö	,	,	Ü	,	· ·	,
5-Year Relative Surviva	al (Percent), 2	005-2011 ^c							
Age at Diagnosis:									
Ages <45	80.4	78.0	84.2	82.3	79.7	86.5	67.2	64.7	71.0
Ages 45-54	78.2	74.9	83.0	80.1	77.2	84.5	62.5	57.2	70.2
Ages 55-64	75.7	72.7	79.7	76.6	73.8	80.4	66.4	60.9	73.7
Ages 65-74	70.6	67.8	73.8	71.2	68.5	74.3	64.8	56.3	71.6
Ages 75+	54.2	53.2	55.1	54.9	53.7	55.9	45.1	42.3	46.1
Ages <65	77.7	74.9	81.8	79.1	76.4	83.1	65.5	61.2	71.7
Ages 65+	61.7	60.4	62.9	62.2	61.0	63.4	56.2	51.3	59.2
Stage ^e :									
All Stages	70.0	68.6	71.6	70.6	69.4	72.0	62.8	59.1	67.2
Localized	82.0	81.7	82.3	82.5	82.5	82.4	77.1	73.0	80.8
Regional	73.8	73.2	74.6	74.4	74.0	74.9	68.7	66.8	70.5
Distant	62.4	60.8	64.4	63.5	61.8	65.5	53.6	50.9	57.3
Unstaged	68.6	67.1	70.1	67.4	66.0	68.9	60.8	57.3	64.1
		· · ·		· · ·	-		· · · · ·		-

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2012.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2012.

Period survival provides a 2011 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2009-2011: 0-1 year survival),

^{(2008-2010: 1-2} year survival), (2007-2009: 2-3 year survival), (2006-2008: 3-4 year survival), (2005-2007: 4-5 years survival).

Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding. The difference between 1975-1977 and 2005-2011 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

Statistic could not be calculated due to fewer than 25 cases during the time period.